ALKS Alkermes plc

+0.17  (+1%)
Previous Close 21.61
Open 21.71
Price To Book 3.1
Market Cap 3,417,379,770
Shares 156,904,489
Volume 1,096,136
Short Ratio
Av. Daily Volume 1,275,108

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced July 2, 2018.
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)
Phase 3 data due early 2020.
Schizophrenia - young adults
Phase 3 data released November 29, 2018 met co-primary endpoints. NDA filing due mid-2019.
CRL received March 15, 2010.
Type 2 diabetes
Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
NDA filing announced December 17, 2018. NDA acceptance announced February 25, 2019. PDUFA estimate December 24, 2019.
Diroximel fumarate (BIIB098)
Multiple sclerosis (MS)
Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 6428
Opioid dependence
CRL announced February 1, 2019.
ALKS 5461
Major depressive disorder
Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
Phase 1/2 commences expansion phase of trial - June 12, 2019.
Solid tumors
Phase 3 data released April 9, 2019 - primary endpoint met.
Aristada and Invega Sustenna
Phase 1 initiation announced February 26, 2019.
ALKS 4230 + Keytruda - ARTISTRY-2
Solid tumors
Phase 3 top-line data due mid-2019.
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera -
Relapsing Remitting Multiple Sclerosis (RRMS)

Latest News

  1. CBM vs. ALKS: Which Stock Should Value Investors Buy Now?
  2. Did You Manage To Avoid Alkermes's (NASDAQ:ALKS) Painful 56% Share Price Drop?
  3. See what the IHS Markit Score report has to say about Alkermes Plc.
  4. Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230
  5. Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma
  6. Here’s What Hedge Funds Think About Alkermes Plc (ALKS)
  7. Biogen Reports Interim Phase III Data on Diroximel Fumarate
  8. New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
  9. Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression
  10. Why Is Alkermes (ALKS) Down 21% Since Last Earnings Report?
  11. Does Alkermes plc's (NASDAQ:ALKS) CEO Salary Compare Well With Others?
  12. Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting
  13. Edited Transcript of ALKS earnings conference call or presentation 25-Apr-19 12:30pm GMT
  14. ALXN or ALKS: Which Is the Better Value Stock Right Now?
  15. Alkermes to Present at the UBS Global Healthcare Conference
  16. Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences
  17. Alkermes Looks Ahead to Growth